Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis
There is solid epidemiologic evidence linking psoriasis and psoriatic arthritis (PsA) to cardiovascular risk factors and an increased risk of developing cardiovascular disease. Chronic inflammation, with shared pathways and cytokines common to metabolic syndrome, atherosclerosis and psoriasis, might...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2017-12-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/19/1/58 |
id |
doaj-87c4121c8a734155b03ef5e0aeab4811 |
---|---|
record_format |
Article |
spelling |
doaj-87c4121c8a734155b03ef5e0aeab48112020-11-24T23:44:14ZengMDPI AGInternational Journal of Molecular Sciences1422-00672017-12-011915810.3390/ijms19010058ijms19010058Cardiometabolic Comorbidities in Psoriasis and Psoriatic ArthritisLluís Puig0Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Sant Quintí 89, 08041 Barcelona, SpainThere is solid epidemiologic evidence linking psoriasis and psoriatic arthritis (PsA) to cardiovascular risk factors and an increased risk of developing cardiovascular disease. Chronic inflammation, with shared pathways and cytokines common to metabolic syndrome, atherosclerosis and psoriasis, might provide the basis for the cardiovascular and metabolic comorbidities of psoriasis and PsA. The purpose of this manuscript is to review recent evidence about the epidemiology and underlying mechanisms of cardiovascular risk factors and cardiovascular disease in patients with psoriasis and/or PsA; the use of analytical determinations, physiologic measures and imaging techniques as surrogate biomarkers of atherosclerosis, endothelial dysfunction and cardiovascular disease in these patients; and the epidemiological and clinical data, including results of clinical trials, supporting a cardioprotective role of anti-inflammatory and disease-modifying treatment in psoriasis and PsA.https://www.mdpi.com/1422-0067/19/1/58psoriasispsoriatic arthritisinflammationcardiovascular diseasecardiovascular riskmetabolic syndromeatherosclerosis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Lluís Puig |
spellingShingle |
Lluís Puig Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis International Journal of Molecular Sciences psoriasis psoriatic arthritis inflammation cardiovascular disease cardiovascular risk metabolic syndrome atherosclerosis |
author_facet |
Lluís Puig |
author_sort |
Lluís Puig |
title |
Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis |
title_short |
Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis |
title_full |
Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis |
title_fullStr |
Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis |
title_full_unstemmed |
Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis |
title_sort |
cardiometabolic comorbidities in psoriasis and psoriatic arthritis |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1422-0067 |
publishDate |
2017-12-01 |
description |
There is solid epidemiologic evidence linking psoriasis and psoriatic arthritis (PsA) to cardiovascular risk factors and an increased risk of developing cardiovascular disease. Chronic inflammation, with shared pathways and cytokines common to metabolic syndrome, atherosclerosis and psoriasis, might provide the basis for the cardiovascular and metabolic comorbidities of psoriasis and PsA. The purpose of this manuscript is to review recent evidence about the epidemiology and underlying mechanisms of cardiovascular risk factors and cardiovascular disease in patients with psoriasis and/or PsA; the use of analytical determinations, physiologic measures and imaging techniques as surrogate biomarkers of atherosclerosis, endothelial dysfunction and cardiovascular disease in these patients; and the epidemiological and clinical data, including results of clinical trials, supporting a cardioprotective role of anti-inflammatory and disease-modifying treatment in psoriasis and PsA. |
topic |
psoriasis psoriatic arthritis inflammation cardiovascular disease cardiovascular risk metabolic syndrome atherosclerosis |
url |
https://www.mdpi.com/1422-0067/19/1/58 |
work_keys_str_mv |
AT lluispuig cardiometaboliccomorbiditiesinpsoriasisandpsoriaticarthritis |
_version_ |
1725499505360502784 |